Phase I-Ib trial of tivantinib in combination with carboplatin and pemetrexed as first-line treatment in patients (pts) with advanced nonsquamous NSCLC or malignant pleural mesothelioma (MPM).

TPS7610 Background: Dysregulation of MET signalling has been reported as a key event in several malignancies and has been identified as a promising therapeutic target. Strong preclinical data on MP...